Primary Sclerosing Cholangitis After Liver Transplant With Oral Vancomycin
Key facts
- Who runs it
- Yael R. Nobel
- Where
- New York, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 21 people, planned
- Started
- Nov 2026
- Expected to end
- Nov 2030
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Oral Vancomycin
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (18)Hide the full registry criteria
Who can take part
- Age ≥ 18 years
- Ability to provide written, informed consent
- History of orthotopic liver transplantation within 1 to 10 years prior to enrollment (i.e. study drug initiation)
- Diagnosis of PSC as the underlying liver disease leading to liver transplantation, based on compatible imaging findings (magnetic resonance cholangiopancreatography [MRCP], endoscopic retrograde cholangiopancreatography [ERCP], percutaneous transhepatic cholangiogram [PTC]), liver histology, and/or clinician judgment
- Subjects with or without IBD may be enrolled. IBD diagnosis with a minimum disease duration of 6 months as assessed by endoscopy/histology. IBD should be in clinical remission or mildly active according to accepted clinical scores and/or clinician judgment
- Stable liver graft function, as determined by ALL of the following criteria:; No episodes of acute rejection within 6 months prior to enrollment, based on liver histology and/or clinical signs or symptoms; No episodes of cholangitis within 6 months prior to study enrollment, based on positive bacterial cultures, compatible imaging, and/or clinical signs or symptoms; No intervention for biliary obstruction (e.g. ERCP, PTC, surgical intervention) within 6 months prior to study enrollment; Stable liver biochemistries within 6 months prior to study enrollment, as determined by: ALP <5x ULN; Absence of histologic or imaging findings suggestive of cirrhosis
Who cannot take part
- History of colon resection at any time prior to study enrollment or presence of ileal/colonic diversion within 12 months prior to study enrollment
- Documented VRE infection within 12 months prior to study enrollment
- Documented C. difficile infection within 3 months prior to study enrollment
- Systemic antibiotic exposure within 3 months prior to study enrollment
- Change in any transplant or IBD-related immunosuppression or its dosing within 30 days prior to study enrollment
- Currently taking oral vancomycin
- Treatment with any investigational drug within 3 months prior to study enrollment
- Allergy or intolerance to vancomycin
- Any active malignancy
- Any condition that, in the investigator's judgment, would make participation unsafe or interfere with adherence (e.g., severe frailty, uncontrolled psychiatric disease, inability to adhere to TID dosing)
- Severe renal dysfunction (eGFR <30 mL/min/1.73 m²) or on dialysis
- Pregnant or breastfeeding Page 8
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Primary sclerosing cholangitis or liver transplant disorder
Where in United States
- Columbia UniversityNew York, United StatesContact: Rebecca YehNot yet recruiting
About the trial
What the trial wants to find out
Primary Objective:
Read full original descriptionShow less
* To evaluate safety of a 4-week course of oral vancomycin (250 mg 3 times daily [TID]) in liver transplant recipients who were transplanted for Primary Sclerosing Cholangitis (PSC).
Secondary Objectives:
* To determine tolerability and adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. * To assess vancomycin resistant enterococcus (VRE) colonization status over time. * To assess the impact of oral vancomycin on stool microbiome composition, diversity, and function. * To assess impact of oral vancomycin on microbial metabolite concentrations in blood and stool. * To assess impact of oral vancomycin on liver-related biochemical markers.
The 2 groups in the trial
- Study Arm - Oral VancomycinTreatment being tested
Patients in study arm will be assigned to receive study drug.
Treatment: Oral Vancomycin
- Control Arm - No DrugNo study treatment, for comparison
Patients in control arm will be assigned to receive no drug.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Preventing Recurrence of Primary Sclerosing Cholangitis After Liver Transplant (PROP-LT): a Phase 1, Open-label, Controlled Study of Oral Vancomycin
- Criteria questions
- Built from NCT07945873, who can take part
- Record updated
- 18 November 2026